Clinical Trial Update: Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of nemolizumab in moderate-to-severe atopic dermatitis with inadequate response to cyclosporine A or for whom cyclosporine A is not advis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Nemolizumab (nemolizumab)

Snippet

Sponsor: Galderma R&D | Conditions: Moderate-to-severe Atopic Dermatitis | Phase 3 | Status: WITHDRAWN